- Home
- TLN vs EXEL Comparison
TLN vs EXEL Comparison
Compare TLN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- EXEL
- Stock Information
- Founded
- TLN 2015
- EXEL 1994
- Country
- TLN United States
- EXEL United States
- Employees
- TLN N/A
- EXEL N/A
- Industry
- TLN Electric Utilities: Central
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLN Utilities
- EXEL Health Care
- Exchange
- TLN Nasdaq
- EXEL Nasdaq
- Market Cap
- TLN 8.1B
- EXEL 9.4B
- IPO Year
- TLN N/A
- EXEL 2000
- Fundamental
- Price
- TLN $217.08
- EXEL $37.42
- Analyst Decision
- TLN Strong Buy
- EXEL Buy
- Analyst Count
- TLN 11
- EXEL 18
- Target Price
- TLN $242.55
- EXEL $37.59
- AVG Volume (30 Days)
- TLN 1.6M
- EXEL 2.8M
- Earning Date
- TLN 02-27-2025
- EXEL 04-29-2025
- Dividend Yield
- TLN N/A
- EXEL N/A
- EPS Growth
- TLN 681.86
- EXEL 170.77
- EPS
- TLN 17.67
- EXEL 1.76
- Revenue
- TLN $2,073,000,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- TLN $9.02
- EXEL $5.45
- Revenue Next Year
- TLN $20.04
- EXEL $10.32
- P/E Ratio
- TLN $12.33
- EXEL $21.43
- Revenue Growth
- TLN N/A
- EXEL 18.50
- 52 Week Low
- TLN $98.50
- EXEL $20.14
- 52 Week High
- TLN $258.03
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- TLN 55.98
- EXEL 58.85
- Support Level
- TLN $198.18
- EXEL $36.68
- Resistance Level
- TLN $211.37
- EXEL $37.99
- Average True Range (ATR)
- TLN 10.99
- EXEL 1.09
- MACD
- TLN 4.07
- EXEL -0.11
- Stochastic Oscillator
- TLN 97.55
- EXEL 49.87
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.